Roxas Accepts Price Controls in Cheaper Medicines Bill (Phillipines)
This article was originally published in PharmAsia News
A large obstacle has been removed clearing the path for legislation designed to allow greater access to affordable medications in the Philippines. Previously, Senator Manual Roxas II had been one of the biggest opponents to a provision in the Philippines House version of the bill that would set up market controls to reduce drug prices. Mr. Roxas' now says that price controls could provide needed insurance if market competition from generics and imports is not sufficient to lower drug prices. Roxas' concession could prove a major leg up for the bill if it passes its readings in the House and the Senate and goes to a bicameral conference. (Click here for more - May Require Free Registration
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.